How Has Data Misuse Hurt COVID-19 Efforts? How Has Data Misuse Hurt COVID-19 Efforts?
WebMD Chief Medical Officer John Whyte talks with Dr Eric Topol about several COVID-19 studies and the need for responsible research, not'sloppy science'that rushes to promote potential treatments.WebMD
We need one million more citizens to volunteer for the COVID-19 vaccine trials. Almost half a million Americans have signed up to be part of the clinical trials, but in order to complete the study, the COVID-19 Prevention Network—formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health—will need more volunteers, and especially more volunteers from diverse backgrounds. The sooner the clinical trials finish accruing patients the sooner we will have results of the vaccine studies. I am a cancer doctor, but like many doctors and researchers have been call...
From February to April 2020, drop>20 percent observed for all primary admission diagnoses
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Publication date: Available online 28 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Serdar Kalemci, Aydın Sarıhan, Arife Zeybek
Publication date: Available online 28 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Mahboobeh Mahdavinia, Christopher Codispoti
Baseline IL-6 serum levels>30 pg/ml identify severe COVID-19 patients and should be used to guide the intervention with IL-6R inhibitors, aiming to improve their use in an uncertain and evolving therapeutic scenario.
The newly described severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is responsible for a pandemic (Corona virus-induced disease -19, COVID-19). It is now well established that certain comorbidities define high risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Since asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical an...
We thank Zwaveling et al1 for appreciating our review2 and for their insightful correspondence. They suggest that suppression of angiotensin-converting enzyme-2 (ACE-2) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could impair the hydrolysis of des-Arg9-bradykinin and stimulate the bradykinin recepto r type 1 (BKB1) pathway to induce leakage of fluid into the lungs. In support of their hypothesis, they stated that loss of ACE-2 in an animal model aggravated acid-induced pulmonary edema, and these effects are alleviated by administration of recombinant human ACE-2.